- Home
- ONFO vs APLM Comparison
ONFO vs APLM Comparison
Compare ONFO & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- APLM
- Stock Information
- Founded
- ONFO 2018
- APLM 2016
- Country
- ONFO United States
- APLM United States
- Employees
- ONFO N/A
- APLM N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- APLM Blank Checks
- Sector
- ONFO Technology
- APLM Finance
- Exchange
- ONFO Nasdaq
- APLM Nasdaq
- Market Cap
- ONFO 5.8M
- APLM 6.9M
- IPO Year
- ONFO 2022
- APLM N/A
- Fundamental
- Price
- ONFO $1.04
- APLM $4.89
- Analyst Decision
- ONFO
- APLM
- Analyst Count
- ONFO 0
- APLM 0
- Target Price
- ONFO N/A
- APLM N/A
- AVG Volume (30 Days)
- ONFO 8.4K
- APLM 6.9K
- Earning Date
- ONFO 05-16-2025
- APLM 04-03-2025
- Dividend Yield
- ONFO N/A
- APLM N/A
- EPS Growth
- ONFO N/A
- APLM N/A
- EPS
- ONFO N/A
- APLM N/A
- Revenue
- ONFO $9,087,118.00
- APLM $198,000.00
- Revenue This Year
- ONFO N/A
- APLM $415.15
- Revenue Next Year
- ONFO N/A
- APLM N/A
- P/E Ratio
- ONFO N/A
- APLM N/A
- Revenue Growth
- ONFO 50.04
- APLM N/A
- 52 Week Low
- ONFO $0.49
- APLM $4.71
- 52 Week High
- ONFO $1.88
- APLM $42.00
- Technical
- Relative Strength Index (RSI)
- ONFO 45.70
- APLM 35.08
- Support Level
- ONFO $1.01
- APLM $4.63
- Resistance Level
- ONFO $1.10
- APLM $5.45
- Average True Range (ATR)
- ONFO 0.02
- APLM 0.54
- MACD
- ONFO -0.00
- APLM -0.10
- Stochastic Oscillator
- ONFO 40.00
- APLM 16.03
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.